{"id":66700,"date":"2026-05-29T14:46:03","date_gmt":"2026-05-29T06:46:03","guid":{"rendered":"https:\/\/flcube.com\/?p=66700"},"modified":"2026-05-29T14:46:05","modified_gmt":"2026-05-29T06:46:05","slug":"sino-biopharmaceutical-and-gsk-report-19-functional-cure-rate-with-bepirovirsen-in-phase-iii-hepatitis-b-studies-at-easl-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66700","title":{"rendered":"Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) announced positive results from two <strong>Phase III clinical studies<\/strong>, <strong>B-Well 1<\/strong> (NCT05630807) and <strong>B-Well 2<\/strong> (NCT05630820), for <strong>bepirovirsen<\/strong> in <strong>chronic hepatitis B (CHB)<\/strong> at the <strong>European Association for the Study of the Liver (EASL) Congress 2026<\/strong>. The investigational therapy, co-developed by Sino Bio subsidiary <strong>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ)<\/strong> and <strong>GlaxoSmithKline plc (GSK)<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>), achieved statistically significant functional cure rates in adult CHB patients.<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-design-amp-key-results\" class=\"wp-block-heading\">Clinical Trial Design &amp; Key Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Trial Names<\/strong><\/td><td>B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820)<\/td><\/tr><tr><td><strong>Phase<\/strong><\/td><td>Phase III<\/td><\/tr><tr><td><strong>Treatment Duration<\/strong><\/td><td>6-month course<\/td><\/tr><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Functional cure rate (HBsAg loss with undetectable HBV DNA)<\/td><\/tr><tr><td><strong>Statistical Significance<\/strong><\/td><td>p&lt;0.001 for primary endpoint<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-pooled-analysis-results\" class=\"wp-block-heading\">Pooled Analysis Results<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Patient Population<\/th><th>Functional Cure Rate<\/th><th>Statistical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Overall Population<\/strong><br>(HBsAg \u22643000 IU\/ml)<\/td><td><strong>19%<\/strong><\/td><td>p&lt;0.001<\/td><\/tr><tr><td><strong>Subgroup Analysis<\/strong><br>(Baseline HBsAg \u22641000 IU\/ml)<\/td><td><strong>26%<\/strong><\/td><td>p&lt;0.001<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-mechanism-amp-innovation\" class=\"wp-block-heading\">Drug Mechanism &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Triple-mechanism antisense oligonucleotide (ASO)<\/li>\n\n\n\n<li><strong>Mechanisms of Action:<\/strong><\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Reduces HBV-related RNA and viral protein production<\/li>\n\n\n\n<li>Lowers blood levels of hepatitis B surface antigen (HBsAg)<\/li>\n\n\n\n<li>Stimulates immune system for durable response<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Goal:<\/strong> Functional cure (sustained HBsAg loss after treatment cessation)<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Acceptable safety and tolerability across both Phase III trials<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-significance-amp-therapeutic-impact\" class=\"wp-block-heading\">Market Significance &amp; Therapeutic Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Medical Need:<\/strong> Current CHB treatments rarely achieve functional cure; most patients require lifelong therapy<\/li>\n\n\n\n<li><strong>Clinical Breakthrough:<\/strong> 19-26% functional cure rates represent substantial improvement over existing standard of care (&lt;1-3% cure rates)<\/li>\n\n\n\n<li><strong>Patient Stratification:<\/strong> Higher efficacy in patients with lower baseline HBsAg (\u22641000 IU\/ml) enables targeted treatment approach<\/li>\n\n\n\n<li><strong>Global Burden:<\/strong> Addresses critical need in hepatitis B-endemic regions affecting 296 million people worldwide<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-dynamics\" class=\"wp-block-heading\">Strategic Partnership Dynamics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Sino Biopharmaceutical<\/th><th>GSK<\/th><\/tr><\/thead><tbody><tr><td><strong>Development Role<\/strong><\/td><td>Co-development through CTTQ subsidiary<\/td><td>Co-development partner<\/td><\/tr><tr><td><strong>Geographic Focus<\/strong><\/td><td>Strong presence in China and Asia-Pacific<\/td><td>Global commercial infrastructure<\/td><\/tr><tr><td><strong>Commercial Rights<\/strong><\/td><td>Details not disclosed in announcement<\/td><td>Likely global rights with regional partnerships<\/td><\/tr><tr><td><strong>Pipeline Integration<\/strong><\/td><td>Expands Sino Bio&#8217;s innovative antiviral portfolio<\/td><td>Strengthens GSK&#8217;s specialty medicines pipeline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-competitive-landscape-in-hepatitis-b-functional-cure\" class=\"wp-block-heading\">Competitive Landscape in Hepatitis B Functional Cure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Approach<\/th><th>Leading Companies<\/th><th>Current Status<\/th><th>Bepirovirsen Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>ASO Therapy<\/strong><\/td><td>Ionis\/GSK (bepirovirsen)<\/td><td><strong>Phase III positive<\/strong><\/td><td><strong>First to demonstrate 19%+ functional cure<\/strong><\/td><\/tr><tr><td><strong>siRNA Therapies<\/strong><\/td><td>Arrowhead, Janssen, Vir<\/td><td>Phase II<\/td><td>Lower reported cure rates<\/td><\/tr><tr><td><strong>Capsid Inhibitors<\/strong><\/td><td>Assembly Biosciences, Roche<\/td><td>Phase II<\/td><td>Primarily suppressive, limited cure data<\/td><\/tr><tr><td><strong>Therapeutic Vaccines<\/strong><\/td><td>Gilead, Transgene<\/td><td>Early development<\/td><td>Immune stimulation component already integrated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for bepirovirsen. Actual results may differ due to risks including final regulatory approvals, market competition, and evolving treatment guidelines for chronic hepatitis B.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052900002_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026052900002_c.\"><\/object><a id=\"wp-block-file--media-4976e996-b7cb-455d-b093-d9f0456b9efe\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052900002_c.pdf\">2026052900002_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052900002_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4976e996-b7cb-455d-b093-d9f0456b9efe\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Limited (HKG: 1177) announced positive results from two Phase III clinical studies, B-Well&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,661,17,278,184,908,914,313],"class_list":["post-66700","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-chia-tai-tianqing-pharmaceutical","tag-clinical-trial-results","tag-glaxosmithkline","tag-gsk","tag-hkg-1177","tag-nyse-gsk","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced positive results from two Phase III clinical studies, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), for bepirovirsen in chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) Congress 2026. The investigational therapy, co-developed by Sino Bio subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ) and GlaxoSmithKline plc (GSK) (NYSE: GSK), achieved statistically significant functional cure rates in adult CHB patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66700\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced positive results from two Phase III clinical studies, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), for bepirovirsen in chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) Congress 2026. The investigational therapy, co-developed by Sino Bio subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ) and GlaxoSmithKline plc (GSK) (NYSE: GSK), achieved statistically significant functional cure rates in adult CHB patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66700\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T06:46:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-29T06:46:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66700#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66700\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026\",\"datePublished\":\"2026-05-29T06:46:03+00:00\",\"dateModified\":\"2026-05-29T06:46:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66700\"},\"wordCount\":435,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"Chia Tai Tianqing Pharmaceutical\",\"Clinical trial results\",\"GlaxoSmithKline\",\"GSK\",\"HKG: 1177\",\"NYSE: GSK\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66700#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66700\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66700\",\"name\":\"Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-29T06:46:03+00:00\",\"dateModified\":\"2026-05-29T06:46:05+00:00\",\"description\":\"Sino Biopharmaceutical Limited (HKG: 1177) announced positive results from two Phase III clinical studies, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), for bepirovirsen in chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) Congress 2026. The investigational therapy, co-developed by Sino Bio subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ) and GlaxoSmithKline plc (GSK) (NYSE: GSK), achieved statistically significant functional cure rates in adult CHB patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66700#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66700\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66700#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced positive results from two Phase III clinical studies, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), for bepirovirsen in chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) Congress 2026. The investigational therapy, co-developed by Sino Bio subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ) and GlaxoSmithKline plc (GSK) (NYSE: GSK), achieved statistically significant functional cure rates in adult CHB patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66700","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026","og_description":"Sino Biopharmaceutical Limited (HKG: 1177) announced positive results from two Phase III clinical studies, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), for bepirovirsen in chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) Congress 2026. The investigational therapy, co-developed by Sino Bio subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ) and GlaxoSmithKline plc (GSK) (NYSE: GSK), achieved statistically significant functional cure rates in adult CHB patients.","og_url":"https:\/\/flcube.com\/?p=66700","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-29T06:46:03+00:00","article_modified_time":"2026-05-29T06:46:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66700#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66700"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026","datePublished":"2026-05-29T06:46:03+00:00","dateModified":"2026-05-29T06:46:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66700"},"wordCount":435,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","Chia Tai Tianqing Pharmaceutical","Clinical trial results","GlaxoSmithKline","GSK","HKG: 1177","NYSE: GSK","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66700#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66700","url":"https:\/\/flcube.com\/?p=66700","name":"Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-29T06:46:03+00:00","dateModified":"2026-05-29T06:46:05+00:00","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced positive results from two Phase III clinical studies, B-Well 1 (NCT05630807) and B-Well 2 (NCT05630820), for bepirovirsen in chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) Congress 2026. The investigational therapy, co-developed by Sino Bio subsidiary Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ) and GlaxoSmithKline plc (GSK) (NYSE: GSK), achieved statistically significant functional cure rates in adult CHB patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66700#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66700"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66700#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical and GSK Report 19% Functional Cure Rate with Bepirovirsen in Phase III Hepatitis B Studies at EASL 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66700"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66700\/revisions"}],"predecessor-version":[{"id":66702,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66700\/revisions\/66702"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}